Trial Profile
A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms Alidial Study
- 10 Feb 2020 Planned End Date changed from 1 Jul 2020 to 31 Dec 2020.
- 10 Feb 2020 Planned primary completion date changed from 31 Dec 2019 to 31 Aug 2020.
- 05 Aug 2019 Planned End Date changed from 1 Sep 2019 to 1 Jul 2020.